Overview

Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

The primary objective is to determine whether inflammatory markers, such as C-Reactive Protein (CRP), Calcitonin Gene-Related Peptide (CGRP), Vasoactive Intestinal Polypeptide (VIP), or Substance P (SP) are reduced in patients having a migraine headache when treated with Imitrex or Treximet. The secondary objective is to determine the effects of Imitrex and Treximet on C-Reactive Protein (CRP) in patients with active migraine headaches.

Details

Lead Sponsor:

Gary E. Ruoff, M.D.

Collaborator:

GlaxoSmithKline

Treatments:

Naproxen
Sumatriptan